Thanks editroid2. You have provided a lot of legitimate commentary here in the past and appreciate it.
I agree. I don't think Chip has any intention of acquiring a pipeline. It's just posturing for a good price when the buyout eventually happens.
There is also additional license potential for Geron as a shell company in licensing the Oligonucleotide IP that looks very promising.
Others have also stated that ALS patients that have major surgery decline more rapidly as a result of the procedure. Therefore, if they were non-responder then their ALS could be worsened. The key is to identify the responders
With 39 sites and counting it does appear it will become a registry study. Only treating 3 or 4 patients per site wouldn't make sense in many ways.
You obviously are unaware of the impressive results they have already reported in the Lancet. Message boards are filled with people making comments about something for which they have little or no knowledge.
Mike, are you familiar with the material that the NSS is made of? It would be interesting to know what the shelf life is as it will affect to cost and method of distribution if approved by the FDA.
Looks like Janssen is trying to categorize patients that have already been treated based on the various administration regimens that Mayo tried. Nice to see the experienced pros in charge.
I would bet they get FDA approval for treatment of acute complete injuries after the first 5 patients. There is no downside to getting the scaffold for these patients. I would be furious if I knew someone with a new SCI if they couldn't get this treatment.
That would be a huge development as uncertainty whether they would be able to identify responder has caused the market to nearly completely devalue NSI-566
I didn't say OPC1 doesn't work. I was just throwing out a hypothetical for discussion. My point was that given what I know now if I had to choose 1 of the 2 trials I would choose the scaffold. That may change as we begin to see the higher dose OPC1 patients treated.
I'm hoping the higher cell count makes the difference and provides spectacular results for the sake of the patients. However, the first two scaffold patients have regained the ability to move their hips and at least 1 has regain bladder and bowel control. The old Geron trial did not have anything this dramatic.
If I had a new spinal cord injury. Although if there was a choice between OPC1 and nothing I would certainly go with OPC1.
It's never going to happen. NVIV is trying to prove it's scaffold works. Throwing stem cells in the mix for this trial would create doubt as to what is causing the patients to improve. This trial will continue on to phase 2 as is for approval. They will probably have another trial with stem cells.
I sure can but I think it will need to be NSI-189 that drives it as the ALS trial will need time to identify responders or prove there is 'no harm" to non responders.